JP Patent

JP2025094218A — Ｊａｋ２阻害剤の結晶形態

Assigned to Impact Biomedicines Inc · Expires 2025-06-24 · 1y expired

What this patent protects

【課題】ＪＡＫ２阻害剤の結晶形態、その組成物、及びＪＡＫ２媒介性障害を治療する方法を提供する。【解決手段】下記構造を有する化合物の結晶形態が提供される。【選択図】図１

USPTO Abstract

【課題】ＪＡＫ２阻害剤の結晶形態、その組成物、及びＪＡＫ２媒介性障害を治療する方法を提供する。【解決手段】下記構造を有する化合物の結晶形態が提供される。【選択図】図１

Drugs covered by this patent

Gavreto (PRALSETINIB) · Rigel Pharms

Patent Metadata

Patent number: JP2025094218A
Jurisdiction: JP
Classification: —
Expires: 2025-06-24
Drug substance claim: No
Drug product claim: No
Assignee: Impact Biomedicines Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.